about
Chylous ascites as the main manifestation of left ventricular dysfunction: a case reportLatin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinomaAntiviral treatment for chronic hepatitis B in renal transplant patientsHepatotoxicity induced by coxibs: how concerned should we be?Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon - Ribavirin in daily practice.Hepatitis C virus diversification in Argentina: comparative analysis between the large city of Buenos Aires and the small rural town of O'Brien.Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3.Imatinib-induced fatal acute liver failureHepatitis C virus infection in Argentina: Burden of chronic disease.Safety of direct-acting antivirals in the treatment of chronic hepatitis C.Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population.Clinical epidemiology of acute hepatitis C in South America.Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.NS3 genomic sequencing and phylogenetic analysis as alternative to a commercially available assay to reliably determine hepatitis C virus subtypes 1a and 1b.[Screening, diagnosis and treatment of chronic hepatitis C in clinical practice].Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir.Syncope during boceprevir treatment in hepatitis C.Entecavir in the treatment of chronic hepatitis B in kidney transplantation.Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin.Acute cholestatic hepatitis after reinitiating treatment with atorvastatin.Hepatitis C virus infection and outcome of renal transplantation.Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups.Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina.Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life'.Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina.Hepatocellular carcinoma in Latin America: Diagnosis and treatment challengesRationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney diseaseWhich Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?[Fulminant hepatic failure. Atypical form of cardiac failure presentation][Fatal acute hepatic failure with hepatocarcinoma presentation in a patient with renal transplant with asymptomatic chronic B and C hepatitis]Severe cholestatic hepatitis as the first symptom of secondary syphilisHBsAg as predictor of outcome in renal transplant patientsPolymyalgia rheumatica presenting as acute cholestatic hepatitis
P50
Q24816070-28E0FF91-7F42-4338-9DB6-274460F55DBCQ26825501-99EE21BB-6405-43F0-9ED4-08EA7A2BBBEFQ28084189-E8FDBE62-F706-41B7-813D-03B950CA31F7Q30244369-B73E12B5-2151-4A30-A42D-7FE697B94E45Q33388856-AEB6D5E1-5488-434B-ADDB-E96B27C96B17Q35080794-CB67DEC9-D9AF-40C2-8A0D-3B8117A215CDQ35308700-1008B589-1FE7-4E84-8F9B-DAB11C3218CDQ36178243-66459A90-DC7A-444F-A06C-BBE5C6B06D89Q36924982-EE0535B0-7106-4040-8572-AA1213AD7DEAQ38189110-442E2580-AF20-4B24-AE84-3B2E1745AB35Q38223361-22809743-1C5E-4746-99CB-82E0915E8EBFQ38303237-54315019-CD38-41AD-BD97-8FD245EA376EQ38859560-AB35F450-F474-422A-A6D1-861A4EBEF198Q39064153-AD4ACB7D-6B29-4691-B0AA-B0658AFBAABCQ39533880-9BB49654-2C54-43F9-94E5-9EDF9A40D1B2Q39715964-D5D65B0F-D7A4-4BA5-8060-6BB8D20A56BEQ40072062-89292C7A-84DA-42E2-86B2-D1E4BA677887Q40104062-D2F23B6B-7C85-43B3-9449-48B37134957CQ40411756-4C438EB4-513D-4700-BF28-3596F6EEF97BQ41562296-5C8F8965-AAB4-43EC-A058-6D6DE154B9FFQ41562307-95EE923E-2093-4830-8EEA-DB4CEE94CE01Q42222932-1D1E7B7F-0455-4A66-B444-2C95F4FEECBEQ42257926-1B610352-552E-4BD8-9DFE-D19432052F70Q43615079-54BDA1AA-DD9F-472D-9D82-3E811C4EAA4EQ43675271-C29AA659-A001-46E8-9C0F-808D2B3F6E51Q43971387-25057E86-585B-4A0E-AAEF-DB33FEE4F6C2Q44036854-B9702491-B27D-45AB-82DF-3A6095B8F61EQ44177370-AB3E1B7F-BD69-4646-BFBB-47D640B0F10CQ45325596-7FCC8471-9035-4B5A-BDF0-9CFA7AD2F8BCQ49199556-0E07985E-F73C-45C2-8E0E-8BE6B136D833Q50557564-B5639B58-A77A-45D5-86A4-982C2B11AB67Q52671959-2726767C-2611-4D9F-9208-C959D5F31B28Q57482215-1F92EE69-C100-4871-A653-3A5CBBAE3B10Q59349225-B9E3C121-9AC9-4D53-878B-6CBC7C1BB4B9Q64229566-91725117-DED2-4E42-875C-28D6C5A7DC3BQ73464714-D23F4A69-3343-4B70-A752-5A320E473D4DQ77227069-233DC091-49E0-4F57-AB18-B169EBE3F786Q80853872-39EF70B4-C604-44B1-B73C-04676EC6A973Q81049661-BAEF4E9F-0D6D-4734-9B08-D8350DC11750Q81688899-C7A4159D-44CF-4751-8F3F-27570819B636
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
E Ridruejo
@ast
E Ridruejo
@en
E Ridruejo
@es
E Ridruejo
@nl
type
label
E Ridruejo
@ast
E Ridruejo
@en
E Ridruejo
@es
E Ridruejo
@nl
prefLabel
E Ridruejo
@ast
E Ridruejo
@en
E Ridruejo
@es
E Ridruejo
@nl
P106
P108
P31
P496
0000-0002-3321-0683